The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

EDUCATION

Research Projects

Project: Understanding the mechanisms that impair anti-tumour Adoptive Cell Therapy

Villadangos Group

Tumour cells express neo-antigens that can be recognised by cytotoxic T lymphocytes (CTL). These tumour-specific CTL can be isolated, expanded and inoculated to kill cancer. Unfortunately, in many individuals the tumour ‘fights back’ and inactivates the infused CTL, compromising the therapy. Using a mouse model of lymphoma, we are performing studies to improve outcomes. Our goal is to apply our findings to the clinic and improve the efficacy of adoptive cell therapy. The aims of this project will be to identify genes that control the outcome of adoptive cell therapy, and characterise the interactions between T cells and the tumour.

Contact project supervisor for further
information and application enquiries

Project Supervisor

Professor Jose Villadangos

Project availability
PhD/MPhil
Master of Biomedical Science
Honours

Villadangos Group

[email protected]

3 vacancies

Themes
Host Pathogens Interactions
Immunology
Cross Cutting Disciplines
Translational and Clinical Research
Discovery Research

The Villadangos group studies the first event that triggers adaptive immune responses: the presentation of pathogen or tumour antigens to T cells by dendritic cells, B cells and macrophages. We are characterising the development, regulation and impairment of antigen presenting cells by pathogens, inflammatory mediators and tumours. We are also dissecting the biochemical machinery involved in antigen capture, processing and presentation. We use this knowledge to understand how T cell-dependent immunity is initiated and maintained, and apply it to design better vaccines and immunotherapies against infectious agents and cancer.


Villadangos Group Current Projects